Literature DB >> 31148248

microRNA-206 overexpression inhibits epithelial-mesenchymal transition and glomerulosclerosis in rats with chronic kidney disease by inhibiting JAK/STAT signaling pathway.

Shi-Qi Zhao1, Zhao-Chun Shen2, Bing-Feng Gao3, Ping Han4.   

Abstract

Chronic kidney disease (CKD) is a traumatic disease with significant psychic consequences to the patient's overall physical condition. microRNA-206 (miR-206) has been reported to play an essential role in the development of various diseases. The purpose of the present study is to investigate the effect of miR-206 through the JAK/STAT signaling pathway on epithelial-mesenchymal transition (EMT) of renal tubular epithelial cells and glomerulosclerosis in rats with CKD. The targeting relationship between miR-206 and ANXA1 was verified. To explore the role of miR-206 in CKD, the model of CKD rats was established to detect glomerular sclerosis index (GSI), contents of interleukin-6 (IL-6) and transforming growth factor-beta1 (TGF-β1), and expression of type IV collagen. Moreover, to further determine the roles of both miR-206 and the JAK/STAT signaling pathway in CKD, the gain- and loss-of function approaches were performed with the expression of ANXA1, α-SMA, E-cadherin, vimentin, N-cadherin, and the JAK/STAT signaling pathway-related genes detected. miR-206 negatively targeted ANXA1. Overexpressed miR-206 inhibited the degeneration and interstitial fibrosis of renal tubular epithelial cells, decreased GSI of rats, and the expression of type IV collagen, TGF-β1 and IL-6. Overexpressed miR-206 inhibited the degeneration of renal tubular epithelial cells, the expression of ANXA1, α-SMA, TGF-β1, p-STAT3, STAT3, p-STAT1, STAT1, p-JAK2, and JAK2, while promoted the expression of E-cadherin. Taken together the results, miR-206 inhibits EMT of renal tubular epithelial cells and glomerulosclerosis by inactivating the JAK/STAT signaling pathway via ANXA1 in CKD.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  JAK/STAT signaling pathway; chronic kidney disease; epithelial-mesenchymal transition; glomerulosclerosis; microRNA-206

Year:  2019        PMID: 31148248     DOI: 10.1002/jcb.28722

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Network Pharmacology and Experimental Verification Strategies to Illustrate the Mechanism of Jian-Pi-Yi-Shen Formula in Suppressing Epithelial-Mesenchymal Transition.

Authors:  Yuan Zhao; Xiangbin Li; Fochang Wang; Shiying Huang; Hanqian Du; Shunmin Li; Jianping Chen
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

Review 2.  MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application.

Authors:  Linsey J F Peters; Jürgen Floege; Erik A L Biessen; Joachim Jankowski; Emiel P C van der Vorst
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

3.  Periodontitis aggravates kidney injury by upregulating STAT1 expression in a mouse model of hypertension.

Authors:  Qin Yang; Handong Ding; Wei Wei; Jie Liu; Jiajia Wang; Jie Ren; Weicheng Chan; Min Wang; Liang Hao; Jinle Li; Yuan Yue
Journal:  FEBS Open Bio       Date:  2021-02-19       Impact factor: 2.693

Review 4.  Therapeutic potential for targeting Annexin A1 in fibrotic diseases.

Authors:  Zhibin Yan; Xurui Cheng; Tao Wang; Xiangyu Hong; Gang Shao; Caiyun Fu
Journal:  Genes Dis       Date:  2022-06-18

5.  FoxO1-mediated inhibition of STAT1 alleviates tubulointerstitial fibrosis and tubule apoptosis in diabetic kidney disease.

Authors:  Fengjuan Huang; Qingzhu Wang; Feng Guo; Yanyan Zhao; Linlin Ji; Tingting An; Yi Song; Yang Liu; Yanyan He; Guijun Qin
Journal:  EBioMedicine       Date:  2019-10-16       Impact factor: 8.143

6.  PERK-Dependent Activation of the JAK2/STAT3 Pathway Contributes to High Glucose-Induced Extracellular Matrix Deposition in Renal Tubular Epithelial Cells.

Authors:  Yan Bao; Wei Liang; Yingchun Ye; Bo Yi
Journal:  Int J Endocrinol       Date:  2021-07-19       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.